Database for high-risk nasopharyngeal carcinoma treated with chemoradiotherapy and immunotherapy
Data files
Dec 04, 2025 version files 54.67 KB
Abstract
This dataset originates from a multicenter, open-label, randomized controlled trial investigating the efficacy of adding anti-PD-1 immunotherapy to concurrent chemoradiotherapy and adjuvant therapy following induction chemotherapy in patients with high-risk nasopharyngeal carcinoma (NPC). The primary research hypothesis is that the intensification of therapy with PD-1 inhibitors during and after concurrent chemoradiotherapy will significantly reduce the disease progression rate and improve overall survival outcomes for this high-risk patient population.
Data includes comprehensive baseline patient characteristics, treatment details, and follow-up data for survival and disease status endpoints.
This data set possesses significant reuse potential. Researchers can perform analyses to validate the primary findings, explore subgroup effects, or generate new hypotheses. Also, it can serve as a benchmark for developing or validating novel statistical methods or prognostic models for survival data analysis. And the dataset can be used for meta-analyses, providing the highest level of evidence to refine the treatment guidelines for high-risk nasopharyngeal carcinoma.
The study protocol was approved by the ethics committee of each participating center. The trial was performed in accordance with the Declaration of Helsinki, and the results were reported according to the CONSORT statement.
Dataset DOI: 10.5061/dryad.3j9kd51zg
Description of the data and file structure
This dataset originates from a multicenter, open-label, randomized controlled trial investigating the efficacy of adding anti-PD-1 immunotherapy to concurrent chemoradiotherapy and adjuvant therapy following induction chemotherapy in patients with high-risk nasopharyngeal carcinoma.
Files and variables
File: Database_for_High-Risk_Nasopharyngeal_Carcinoma_Treated_with_Chemoradiotherapy_and_Immunotherapy.xlsx
Description: The primary dataset is provided in a single Excel file. The variables are described below. Missing data in this dataset is indicated by "NA".
Variables
- No. : Patient ID
- center: The medical center where the patient received treatment, each number represents a hospital
- TNM stage: The TNM stage classification of the cancer
- overall response (Y/N): Whether the patient responded to the induction chemotherapy or not (e.g., Yes/No)
- ITT group: The group to which the patient was randomly assigned (1-Standard therapy group; 2-Camrelizumab group)
- safety set: Whether the patient is included in the safety set (1-Yes; 2-No)
- PP set: Whether the patient is included in the Per-Protocol set (1-Yes; 2-No)
- Pathological Type: The pathological type of the cancer (e.g., Nonkeratinizing undifferentiated/Nonkeratinizing differentiated)
- T stage: The extent of the primary tumor (T category)
- N stage: The degree of spread to regional lymph nodes (N category)
- M stage: The presence or absence of distant metastasis (M category)
- KPS: The Karnofsky Performance Status score, assessing the patient's functional capacity (Range: 0-100)
- Imaging After 3 Cycles of IC: The radiological assessment of the tumor following three cycles of induction chemotherapy (SD-stable disease; PR-partial response; CR-complete response)
- EBV Clearance Status: Whether the Epstein-Barr virus DNA was cleared after induction chemotherapy or not (0-No; 1-Yes)
- Survival (Y/N): Whether the patient has died or not (0-No; 1-Yes)
- OS: Overall survival (Unit: Months)
- progression (Y/N): Whether the patient has experienced loco-regional relapse, distant metastasis, or death from any cause or not (0-No; 1-Yes)
- PFS: Progression-free survival (Unit: Months)
- Recurrence (Y/N): Whether the patient has had locoregional relapse or not (0-No; 1-Yes)
- LRRFS: locoregional relapse-free survival (Unit: Months)
- Metastasis (Y/N): Whether the patient has had distant metastasis or not (0-No; 1-Yes)
- DMFS: Distant metastasis-free survival (Unit: Months)
Code/software
No specialized code or software is required to view the dataset. The data file is provided in Microsoft Excel (.xlsx) format and can be opened and examined using standard spreadsheet software.
Access information
Other publicly accessible locations of the data:
Data was derived from the following sources:
- This is a primary dataset derived from the original clinical trial: NCT04453826